The 36-month beta value for LXRX is also noteworthy at 1.09. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for LXRX is 180.38M, and at present, short sellers hold a 22.91% of that float. The average trading volume of LXRX on May 09, 2025 was 15.60M shares.
LXRX) stock’s latest price update
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX)’s stock price has gone rise by 0.60 in comparison to its previous close of 0.69, however, the company has experienced a -4.89% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-05-06 that THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on Tuesday, May 20, at 9:30 a.m. ET.
LXRX’s Market Performance
Lexicon Pharmaceuticals Inc (LXRX) has experienced a -4.89% fall in stock performance for the past week, with a 37.52% rise in the past month, and a -6.88% drop in the past quarter. The volatility ratio for the week is 8.98%, and the volatility levels for the past 30 days are at 11.78% for LXRX. The simple moving average for the last 20 days is 9.40% for LXRX’s stock, with a simple moving average of -36.74% for the last 200 days.
Analysts’ Opinion of LXRX
Many brokerage firms have already submitted their reports for LXRX stocks, with Leerink Partners repeating the rating for LXRX by listing it as a “Market Perform.” The predicted price for LXRX in the upcoming period, according to Leerink Partners is $1 based on the research report published on March 05, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LXRX reach a price target of $10. The rating they have provided for LXRX stocks is “Buy” according to the report published on June 17th, 2024.
Leerink Partners gave a rating of “Outperform” to LXRX, setting the target price at $5 in the report published on April 30th of the previous year.
LXRX Trading at 37.40% from the 50-Day Moving Average
After a stumble in the market that brought LXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.87% of loss for the given period.
Volatility was left at 11.78%, however, over the last 30 days, the volatility rate increased by 8.98%, as shares surge +40.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.48% lower at present.
During the last 5 trading sessions, LXRX fell by -4.89%, which changed the moving average for the period of 200-days by -65.37% in comparison to the 20-day moving average, which settled at $0.6299. In addition, Lexicon Pharmaceuticals Inc saw -6.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LXRX starting from COATS LONNEL, who proposed sale 300,000 shares at the price of $1.60 back on Aug 15 ’24. After this action, COATS LONNEL now owns shares of Lexicon Pharmaceuticals Inc, valued at $480,000 using the latest closing price.
Stock Fundamentals for LXRX
Current profitability levels for the company are sitting at:
- -6.34 for the present operating margin
- 0.98 for the gross margin
The net margin for Lexicon Pharmaceuticals Inc stands at -6.45. The total capital return value is set at -0.78. Equity return is now at value -167.66, with -75.93 for asset returns.
Based on Lexicon Pharmaceuticals Inc (LXRX), the company’s capital structure generated 0.43 points at debt to capital in total, while cash flow to debt ratio is standing at -1.65. The debt to equity ratio resting at 0.74. The interest coverage ratio of the stock is -12.65.
Currently, EBITDA for the company is -184.29 million with net debt to EBITDA at -0.23. When we switch over and look at the enterprise to sales, we see a ratio of 9.4. The receivables turnover for the company is 8.95for trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.44.
Conclusion
In summary, Lexicon Pharmaceuticals Inc (LXRX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
